The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients (CACOVID-19)
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Sponsor: ARCAGY/ GINECO GROUP
A observational or N/A phase clinical study on COVID and Cancer, this trial is completed. The trial is conducted by ARCAGY/ GINECO GROUP and has accumulated 11 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Oct 2021 — May 2022 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Mar 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Recruiting
-
Jun 2020 — Sep 2020 [monthly]
Recruiting
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ARCAGY/ GINECO GROUP
- Association de Neuro-Oncologues d'Expression Francaise
- Federation Francophone de Cancerologie Digestive
- GERCOR - Multidisciplinary Oncology Cooperative Group
- GORTEC
- Intergroupe Francophone de Cancerologie Thoracique
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbeville, France , Amiens, France , Angers, France , Antony, France , Argenteuil, France , Ars-Laquenexy, France , Auch, France , Auxerre, France , Avignon, France , Bayeux, France and 105 more locations